ST. PAUL, Minn., Jan. 30, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
Date: | Thursday, February 27, 2025 |
Time: | 3:30 p.m. CST / 4:30 p.m. EST |
Location: | |
U.S. dial-in | +1 (800) 715-9871 |
International dial-in: | +1 (646) 307-1963 |
Conference ID: | 6342275 |
A replay of the webcast, the earnings press release, presentation slides, and supplemental financial disclosures, will be available on the Investor Relations section of Solventum's website.
Other upcoming Investor Events:
2025 Investor Day | Mid-March (location: NYC) Additional details to follow |
Solventum plans to host an Investor Day in March in New York City to introduce its strategy to accelerate growth and its long-range financial plan. More details and registration information will be shared soon.
About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.
Last Trade: | US$65.67 |
Daily Change: | -0.26 -0.39 |
Daily Volume: | 603,005 |
Market Cap: | US$11.350B |
March 12, 2025 February 27, 2025 November 14, 2024 November 07, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load